| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8772544 | Kidney International | 2018 | 5 Pages |
Abstract
Fibroblast growth factor 23 (FGF23) has appeared as a hormone that is massively elevated in patients with chronic kidney disease. Whether FGF23 is a risk factor that associates with cardiac pathologies and cardiovascular mortality, as suggested by a variety of clinical studies, or additionally acts as a causative factor that induces cardiac injury, as more recently indicated by cell culture and animal studies, is under debate and the center of many ongoing experimental studies.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Christian Faul,